Profile data is unavailable for this security.
About the company
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
- Revenue in USD (TTM)0.00
- Net income in USD-68.80m
- Incorporated2017
- Employees58.00
- LocationPassage Bio IncOne Commerce Square2005 Market Street, 39Th FloorPHILADELPHIA 19103United StatesUSA
- Phone+1 (267) 866-0312
- Fax+1 (302) 655-5049
- Websitehttps://www.passagebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hcw Biologics Inc | 3.50m | -37.33m | 29.79m | 45.00 | -- | -- | -- | 8.52 | -1.00 | -1.00 | 0.0939 | -0.2636 | 0.1125 | -- | 5.13 | 77,688.45 | -120.09 | -- | -279.71 | -- | 32.41 | -- | -1,067.83 | -- | -- | -93.78 | 4.52 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Impact Biomedical Inc | 0.00 | 1.16m | 30.12m | 1.00 | 25.98 | 0.9633 | 13.58 | -- | -0.2094 | -0.2094 | 0.00 | 2.72 | 0.00 | -- | -- | 0.00 | 2.39 | -- | 3.04 | -- | -- | -- | -- | -- | -- | -- | 0.189 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Surrozen Inc | 10.00m | -44.44m | 30.22m | 42.00 | -- | 5.33 | -- | 3.02 | -17.05 | -17.05 | 3.81 | 1.74 | 0.1961 | -- | 1.41 | 238,095.20 | -87.16 | -- | -99.66 | -- | -- | -- | -444.38 | -- | -- | -1.43 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Clene Inc. | 421.00k | -36.02m | 30.40m | 82.00 | -- | -- | -- | 72.22 | -5.58 | -5.58 | 0.0652 | -0.6016 | 0.0092 | 0.7759 | 13.16 | 5,134.15 | -78.31 | -39.43 | -136.18 | -47.32 | 78.62 | -- | -8,556.77 | -5,261.20 | 0.8213 | -10.15 | 1.30 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -563.35k | 31.22m | 6.00 | -- | 4.29 | -- | -- | -0.1931 | -0.1931 | 0.00 | 0.2225 | 0.00 | -- | -- | 0.00 | -2.66 | -144.28 | -3.77 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -19.09m | 31.81m | 21.00 | -- | 1.20 | -- | -- | -1.77 | -1.77 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -48.91 | -28.83 | -52.88 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 31.89m | 22.00 | -- | 0.3482 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -8.82m | 32.21m | -- | -- | 43.15 | -- | -- | -0.2378 | -0.2378 | 0.00 | 0.0206 | 0.00 | -- | -- | -- | -56.73 | -- | -163.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 32.42m | 163.00 | -- | 0.1589 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -11.61m | 32.75m | 32.00 | -- | 0.5835 | -- | -- | -1.08 | -1.08 | 0.00 | 5.54 | 0.00 | -- | -- | -- | -16.17 | -31.68 | -16.64 | -33.95 | -- | -- | -- | -56,271.43 | -- | -- | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| Passage Bio Inc | 0.00 | -68.80m | 33.11m | 58.00 | -- | 0.4553 | -- | -- | -1.17 | -1.17 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -48.97 | -48.56 | -56.34 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Curis Inc | 10.26m | -45.48m | 34.04m | 48.00 | -- | -- | -- | 3.32 | -7.81 | -7.81 | 1.76 | -1.45 | 0.1549 | -- | 3.52 | 213,729.20 | -68.68 | -37.25 | -94.06 | -41.12 | 98.68 | 96.05 | -443.35 | -409.44 | -- | -- | -- | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Carisma Therapeutics Inc | 20.27m | -63.80m | 35.40m | 107.00 | -- | -- | -- | 1.75 | -1.56 | -1.56 | 0.4927 | -0.2665 | 0.2723 | -- | -- | 189,420.60 | -85.73 | -30.87 | -101.81 | -34.47 | -- | -- | -314.78 | -255.66 | -- | -- | -- | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Elevation Oncology Inc | 0.00 | -41.95m | 35.78m | 29.00 | -- | 0.5159 | -- | -- | -0.807 | -0.807 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -40.67 | -- | -43.53 | -- | -- | -- | -- | -- | -- | -375.06 | 0.309 | -- | -- | -- | 51.93 | -- | -- | -- |
| NextCure Inc | 0.00 | -58.52m | 36.13m | 82.00 | -- | 0.4774 | -- | -- | -2.09 | -2.09 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -50.82 | -22.59 | -54.42 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
Data as of Nov 22 2024. Currency figures normalised to Passage Bio Inc's reporting currency: US Dollar USD
39.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Lynx1 Capital Management LPas of 30 Sep 2024 | 8.43m | 13.64% |
| Vestal Point Capital LPas of 30 Sep 2024 | 6.10m | 9.88% |
| Erste Asset Management GmbHas of 30 Sep 2024 | 2.46m | 3.98% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.06m | 3.33% |
| Tang Capital Management LLCas of 30 Sep 2024 | 1.50m | 2.43% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 1.39m | 2.26% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 961.27k | 1.56% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 659.33k | 1.07% |
| Bridgeway Capital Management LLCas of 30 Sep 2024 | 556.14k | 0.90% |
| Geode Capital Management LLCas of 30 Sep 2024 | 509.52k | 0.83% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
